Recent progress in the development and testing of vaccines against human tuberculosis. (Q30332918)

18 June 2017

1 reference

title

Recent progress in the development and testing of vaccines against human tuberculosis. (English)

1 reference

18 June 2017

0 references

David N McMurray

1

1 reference

18 June 2017

publication date

1 May 2003

1 reference

International Journal for Parasitology

18 June 2017

published in

1 reference

18 June 2017

volume

33

1 reference

18 June 2017

issue

5-6

1 reference

18 June 2017

page(s)

547-554

1 reference

TB vaccines: progress and problems.

18 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Comparative genomics of BCG vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Boosting vaccine for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Improved tuberculosis DNA vaccines by formulation in cationic lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

A proposed national strategy for tuberculosis vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

CpG oligodeoxynucleotides enhance host defense during murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

How can immunology contribute to the control of tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Naturally attenuated, orally administered Mycobacterium microti as a tuberculosis vaccine is better than subcutaneous Mycobacterium bovis BCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Disease model: pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Tuberculosis vaccine development: recent progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Influence of Mycobacterium bovis Bacillus Calmette-Guerin on Antibody and Cytokine Responses to Human Neonatal Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

BCG vaccination against tuberculosis: past disappointments and future hopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

An analysis of some hypotheses related to the Chingelput bacille Calmette-Guérin trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900061-4

10.1016/S0020-7519(03)00061-4

7 January 2021

Identifiers

DOI

1 reference

18 June 2017

1 reference